A retrospective study assessing the patient characteristics, prior treatment patterns and time to diagnosis in patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome without Hematopoietic Cell Transplantation in the United States
Latest Information Update: 29 Jan 2022
Price :
$35 *
At a glance
- Drugs Antineoplastics (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dactinomycin (Primary) ; Daunorubicin (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Fludarabine (Primary) ; Fluorouracil (Primary) ; Gemtuzumab ozogamicin (Primary) ; Inotuzumab ozogamicin (Primary) ; Oxaliplatin (Primary) ; Pegaspargase (Primary) ; Tioguanine (Primary) ; Vincristine (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 29 Jan 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition